Our work, thus, strongly advocates that FoxM1 overexpression offers HCC cells a remarkable growth advantage (Figures 3A, B) and its targeted knockdown successfully sensitized conventionally resistant tumor cells to therapeutic regimes, including Artemisinin (Figures 3D–G, 4). The gene discussed is FOXM1; the disease is neoplasm.